NEW YORK (GenomeWeb) – Editas Medicine announced today that it has signed a licensing deal with Massachusetts General Hospital for intellectual property related to the use of CRISPR/Cas9 and TALEN genome-editing technologies for human and veterinary therapeutic applications, as well as broad agricultural use.

Separately, Editas said that it had struck similar deals with Duke University, Harvard University, and the Broad Institute for CRISPR/Cas9 and TALENs IP for the development of human therapeutics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.